News

Find News

Filter articles

Applied Filters

Showing 1 to 10 of 1799 results

Illumina escapes genetics trade secrets claims

US17-01-2020Rory O'Neill

A US judge has thrown out a lawsuit accusing US biotechnology companies Illumina and Affymetrix of a “complex, multi-decade concerted effort” to conceal the theft of trade secrets in the 1990s.

Idenix angered by confirmation of hepatitis C treatment patent decision

US17-01-2020Edward Pearcey

Biopharmaceutical company Idenix has cited the “profound consequences for genus claims” in attacking a federal court ruling that affirmed a decision made in a patent dispute with Gilead Sciences.

Gilead hit with antitrust suit over HIV drugs

US16-01-2020Sarah Morgan

Gilead and its alleged co-conspirators Bristol-Myers Squibb, Japan Tobacco, and Johnson & Johnson have been accused of engaging in a long-running scheme to suppress competition in the market for HIV prevention therapies.

California mulls state generics brand

US13-01-2020Rory O'Neill

California’s governor wants the state to establish its own generics brand in a bid to bring down the cost of prescription drugs.

Judge refuses to block pay-for-delay law pending appeal

US13-01-2020Sarah Morgan

A judge has refused to temporarily block California’s ban on pay-for-delay deals while a group of generics manufacturers appeal against the judge’s earlier decision.

Senju, Bausch settle eye drop litigation against Indian generics maker

US09-01-2020Rory O'Neill

Senju Pharmaceutical and Bausch Health have reached an “amicable settlement” to its patent suit against Aurobindo over generic Prolensa eye drops, court filings confirm.

Fed Circuit issues mixed Sensipar verdict for Amgen

US09-01-2020Sarah Morgan

In a partial victory for Amgen, the US Court of Appeals for the Federal Circuit concluded that a proposed generic version of Amgen’s drug Sensipar would infringe a patent earlier this week.

Allergan agrees to pay $300m to end birth control litigation

US08-01-2020Sarah Morgan

Allergan’s Warner Chilcott and Watson subsidiaries have agreed to pay $300 million to end antitrust litigation centering on contraceptive pills Loestrin 24 Fe and Minastrin 24 Fe.

USPTO rejects DNA sequencing trademark

US08-01-2020Rory O'Neill

A San Diego biotechnology company has been refused a trademark registration for ‘Sequencing by Binding’ on the grounds that it is too descriptive.

Judge approves $120m Momenta and Sandoz settlement

US06-01-2020Rory O'Neill

A US federal judge has given preliminary approval to the proposed settlement in the class action suit led by Nashville General Hospital against Momenta Pharmaceuticals and Sandoz over their alleged manipulation of drug testing protocols.

Showing 1 to 10 of 1799 results

LSIPR